INTERVIEW: Merck Serono CEO On Growing In A Slowing China
This article was originally published in PharmAsia News
Despite a slowing Chinese economy and a plethora of layoffs announced by multinational drug makers, Merck KGaA sees growth opportunities via localization and partnering in China. But MNCs have to fully grasp the volatility embedded in the emerging markets, says Merck Serono CEO Belén Garijo.
You may also be interested in...
Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.